RGEN | Ticker Profile - Titan Protect

RGEN

Repligen Corporation

Healthcare · Medical Instruments & Supplies · NMS

$122.31

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$6.4B

Total market value of the company

Trailing P/E

124.36

Expensive — high growth expected

Forward P/E

44.34

Based on estimated future earnings — lower means cheaper

Rev Growth

+14.8%

Year-over-year revenue change

Profit Margin

6.7%

How much profit the company keeps from each dollar of revenue

ROE

2.5%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$180.00

+47% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 19 analysts covering this stock

About Repligen Corporation

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

https://www.repligen.com

Country: United States Employees: 2,000 Industry: Medical Instruments & Supplies

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

0.038

Positive but modest risk-adjusted returns

Kelly Fraction

0.0032

Marginal edge — very small allocation suggested

Calmar Ratio

-0.250

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-10.2%

Historical annualised return based on price data

Max Drawdown

-41.0%

Largest peak-to-trough decline — the worst it has been

HMM State

BULL

Statistical model sees bullish momentum

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.09

Moves slightly more than the broader market

52W High

$175.77

30% below the year high

52W Low

$100.99

21% above the year low

Avg Volume

1,076,881

Average daily shares traded — higher means easier to buy and sell

Short Ratio

4.4

Days it would take all short sellers to cover — higher means more crowded

Short % Float

10.1%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$0.91

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

32.66

Heavy leverage — higher financial risk if revenues decline

Current Ratio

9.20

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

7.45

Like current ratio but excludes inventory — stricter test

Gross Margin

53.1%

Revenue left after cost of goods — higher means pricing power

Operating Margin

8.9%

Profit from core operations before interest and tax

Free Cash Flow

$69M

Positive — the business generates more cash than it spends

Revenue (TTM)

$763M

Total revenue over the last 12 months

Net Income

$51M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$220.00

Target Median

$180.00

Target Low

$142.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go